Serous Retinal Detachment: Causes, Symptoms, & Treatment

Serous retinal detachment occurs when fluid accumulates beneath the retina without a tear or hole in the retinal tissue, lifting it away from the supportive layer underneath. Unlike the more familiar tear-related (rhegmatogenous) detachment, a serous detachment is driven by an underlying condition that pushes or leaks fluid into a space where it does not belong. The causes range from stress-related vascular changes and corticosteroid use to severe hypertension, autoimmune inflammation, and tumors. Because the mechanism differs from a retinal tear, the treatment strategy is different too, often focusing on the root cause rather than emergency surgery.

What Makes a Serous Detachment Different

The retina normally sits flush against a single-cell layer called the retinal pigment epithelium (RPE), which actively pumps fluid out of the space between these two layers. For fluid to accumulate and cause a serous detachment, something has to drive fluid inward faster than the RPE can pump it out, or the RPE itself has to become compromised. Animal experiments have confirmed that fluid does not ordinarily persist in this subretinal space because it is rapidly transported across the RPE by active ionic transport.¹ A serous detachment, then, signals that something has overwhelmed this built-in drainage system.

In a rhegmatogenous detachment, vitreous gel seeps through a physical break in the retina and peels it away mechanically. In a serous (also called exudative) detachment, there is no break. Instead, an inflammatory condition, vascular abnormality, or tumor forces exudative fluid into the subretinal space beyond what the RPE can handle.² This distinction matters clinically. One recent study found that a specific imaging feature called outer retinal corrugations appeared in 80% of eyes with tear-related detachments but in none of the eyes with exudative detachments, illustrating how structurally different the two conditions are under high-resolution scans.³

The Most Common Causes

Serous detachments have a wide range of triggers, but they cluster into a few major categories.

Central Serous Chorioretinopathy

Central serous chorioretinopathy (CSCR) is the single most common cause of serous detachment in younger, otherwise healthy adults. The basic problem involves thickening and congestion of the choroid, the blood-vessel-rich layer beneath the retina. This leads to hyperpermeability, meaning fluid leaks through the RPE and pools under the retina.⁴ The condition is well known for its association with psychological stress, certain personality traits, and corticosteroid use in any form, whether oral, inhaled, injected, or even topical skin creams.⁵ CSCR predominantly affects men, though it also shows up at increased rates in pregnant and menopausal women, pointing to a hormonal component.⁶

Severe Hypertension and Preeclampsia

Dangerously high blood pressure can damage the small blood vessels in the choroid, starving portions of the RPE of their blood supply and causing fluid to leak underneath the retina. This mechanism has been documented in both malignant hypertension and preeclampsia, a condition of pregnancy marked by high blood pressure and organ dysfunction.⁷ In preeclampsia, the detachment can be dramatic. One case report described a 29-year-old woman who developed sudden bilateral vision loss from bullous serous detachment in both eyes after delivery.⁸ In most preeclampsia cases, the detachment resolves spontaneously once blood pressure is controlled, but it serves as a warning sign of how much vascular stress the body is under.

Inflammatory and Autoimmune Disease

Vogt-Koyanagi-Harada (VKH) disease is a classic example. This autoimmune condition targets pigmented tissues throughout the body, and the choroid is a prime target. Among 96 patients with newly diagnosed VKH disease in one study, the vast majority (82 patients) presented with the serous-detachment form rather than the optic-disc-swelling form, making it the dominant way the disease affects the eye.⁹ Other inflammatory conditions, including posterior scleritis, sarcoidosis, and various forms of uveitis, can produce serous detachments through similar choroidal inflammation pathways.

Tumors

Both benign and malignant growths in the choroid can cause serous detachment by disrupting normal vascular architecture and leaking fluid. Exudative retinal detachment is actually the most common source of visual loss associated with uveal melanoma, the most frequent primary eye cancer in adults.¹⁰ The detachment can sometimes be so extensive that the underlying tumor is initially hidden beneath the ballooned-up retina, delaying diagnosis.¹¹ Benign choroidal hemangiomas can do the same thing, producing exudative detachments that require treatment of the vascular tumor itself.¹²

Medications That Can Trigger Serous Detachment

Corticosteroids are the most thoroughly documented pharmacological trigger. Any route of administration counts, and the effect can appear quickly. In one reported case, a 24-year-old man developed visual symptoms after just three days on oral prednisolone for facial palsy, with the detachment confirmed on angiography and resolving once the steroid was tapered.¹³ The tricky part is that many people take steroids for legitimate reasons and have no idea they carry this eye risk.

The list of implicated drugs extends well beyond steroids. A comprehensive review identified sympathomimetic agents (decongestants, stimulants), psychotropic medications, phosphodiesterase inhibitors (including erectile dysfunction drugs), hormonal therapies, and even some targeted cancer drugs as potential triggers. The common thread appears to be any substance that alters choroidal blood flow or activates pathways involving cortisol or the sympathetic nervous system.⁶ MEK inhibitors, a class of targeted cancer therapy, have been specifically reported to cause bilateral subfoveal serous detachment. In three patients treated with oral MEK inhibitors for metastatic cancers, all developed bilateral detachments, though all resolved either spontaneously or with observation.¹⁴

If you develop visual symptoms while on any of these medications, the key step is to tell your eye doctor exactly what you are taking. In many drug-induced cases, stopping or switching the medication is the most effective treatment.

What Serous Detachment Feels Like

Symptoms depend on where the fluid collects. When it pools under the central macula, you are likely to notice blurred or dimmed central vision, sometimes described as looking through a smudged window. Objects may appear smaller than they actually are (micropsia) or slightly distorted. Colors can seem washed out in the affected eye. Some people notice a dark or grayish spot in their central vision. Peripheral vision usually stays intact because the detachment tends to be localized rather than total.

In milder cases, especially with acute CSCR, the changes can be subtle enough that you write them off as tired eyes or a need for new glasses. In more severe presentations, like bullous detachments from preeclampsia or a large choroidal tumor, vision loss can be sudden and dramatic.

One often-overlooked dimension is the psychological burden. Patients with CSCR report significantly higher levels of psychological distress and lower quality of life compared to people without the condition.¹⁵ This creates something of a vicious cycle: stress is a known trigger for CSCR, and having CSCR increases stress and anxiety.¹⁶ Patients who use more psychotropic medications and report higher baseline anxiety scores appear to be at elevated risk, making mental health an underappreciated part of managing this condition.

How It Is Diagnosed

A dilated eye exam is the starting point. The fluid collection under the retina often gives the macula a dome-shaped or blister-like appearance that an experienced eye doctor can spot directly. But the real diagnostic workhorses are imaging technologies.

Optical coherence tomography (OCT) is the go-to tool. It produces cross-sectional images of the retina at near-cellular resolution, making subretinal fluid instantly visible as a dark pocket lifting the retina away from the RPE. OCT can also distinguish serous detachment from other forms of retinal swelling and track fluid volume over time. Automated deep-learning algorithms can now detect and measure subretinal fluid on OCT scans with high accuracy, achieving strong correlation with manual measurements by expert graders.¹⁷ Research groups have even demonstrated that transfer-learning approaches can adapt these algorithms across different OCT device brands, broadening their practical use.¹⁸

Fluorescein angiography (FA) involves injecting a dye into a vein and photographing how it circulates through the retinal and choroidal blood vessels. In CSCR, it typically shows a characteristic “inkblot” or “smokestack” pattern of dye leaking through a pinpoint RPE defect. Indocyanine green angiography (ICGA) provides a complementary view, highlighting choroidal congestion and hyperpermeability that FA might miss. In conditions like VKH disease, combining both angiographic methods is particularly useful for early diagnosis and for monitoring treatment response.¹⁹

Ultrasound (B-scan) becomes important when the detachment is so extensive that the retina blocks the view of deeper structures. If a choroidal tumor is suspected, ultrasound can reveal its shape, size, and internal reflectivity, helping to differentiate a melanoma from a hemangioma or metastatic deposit.¹²

Treatment Approaches

Because serous detachment is a symptom of an underlying problem rather than a standalone disease, treatment always begins with identifying and addressing that root cause. The specific strategy varies widely depending on what is driving the fluid.

Observation and Lifestyle Changes for Acute CSCR

Most cases of acute CSCR resolve on their own within a few months. The standard first-line approach is observation combined with practical steps: stopping corticosteroids if at all possible, reducing psychological stress, controlling blood pressure, and improving sleep quality. For many people, this is all that is needed.²⁰ The challenge is that “reduce stress” is easy advice to give and hard advice to follow, especially when the vision problem itself is a source of anxiety.

Medications

When CSCR becomes chronic or keeps recurring, medications may be tried. The evidence base for most drugs is thin, but mineralocorticoid receptor antagonists (like eplerenone and spironolactone) have shown the most promise among systemic options.²⁰ These drugs work by blocking the effect of aldosterone on choroidal blood vessels, potentially reducing the permeability that fuels fluid leakage. For autoimmune causes like VKH, systemic immunosuppression with corticosteroids and steroid-sparing agents is the mainstay, which is ironic given that steroids can cause CSCR in other contexts. The dosing and tapering of immunosuppressives in VKH requires careful monitoring.

Laser and Photodynamic Therapy

Photodynamic therapy (PDT) with verteporfin has become a leading treatment for chronic CSCR that does not resolve on its own. The drug is injected intravenously and then activated by a low-energy laser applied to the affected area of the choroid. This causes selective closure of leaking choroidal vessels without damaging the overlying retina. In a pilot study of chronic CSCR, a single session of PDT combined with an anti-VEGF injection achieved complete resolution of subretinal fluid in all treated eyes at 12 months, with visual acuity improving from roughly 20/80 to 20/30 on average.²¹ Another study of recalcitrant chronic CSCR found that all eight patients achieved complete fluid resolution after combination PDT and anti-VEGF treatment, with no recurrence in seven of eight patients over about 13 months of follow-up.²²

Focal laser photocoagulation is an older approach that can seal a visible leak point, but it carries a risk of creating a permanent blind spot in the treated area and is generally reserved for leaks that are located well away from the center of vision.

Surgery for Resistant Cases

Vitrectomy, where the gel inside the eye is surgically removed, is not a first-line option for serous detachment, but it can play a role when inflammatory exudative detachments fail to respond to medications. In a series of 12 eyes with treatment-resistant inflammatory exudative detachment that underwent vitrectomy, half experienced recurrence, though some of those could then be controlled medically. The authors concluded that vitrectomy can function as an adjuvant to conventional medical therapy, helping to maintain structural integrity of the retina when drugs alone are not enough.²³

Prognosis and When Vision Does Not Fully Recover

For most cases of acute CSCR, the outlook is good. The fluid reabsorbs within a few months, and vision returns to normal or near-normal. But chronic or recurrent episodes paint a different picture. Prolonged fluid under the retina can damage the photoreceptor cells and the RPE, leading to permanent changes in central vision even after the fluid clears. People with chronic CSCR sometimes describe lasting subtle distortions, contrast sensitivity loss, or a persistent dim spot that never quite goes away.

For serous detachments caused by preeclampsia or acute hypertensive crises, the prognosis is generally favorable once blood pressure is brought under control. The retina usually reattaches spontaneously. In tumor-related cases, the visual prognosis depends heavily on the size and location of the tumor and on how quickly treatment begins. A choroidal melanoma that has already caused extensive detachment may leave lasting visual impairment even if the cancer is treated successfully.

Why Stress Keeps Coming Up

Stress occupies a unique position in the story of serous detachment. It is both the best-known risk factor for CSCR and one of the hardest to address. The proposed mechanism involves activation of the body’s cortisol response. Under stress, the adrenal glands release cortisol, which among many other effects can alter choroidal blood flow and increase vascular permeability. This is essentially the same pathway triggered by exogenous corticosteroid drugs, which explains why both emotional stress and steroid pills can produce the same eye condition.⁴

Obstructive sleep apnea has also been linked to CSCR through a related mechanism: the repeated oxygen drops and surges of stress hormones during apneic episodes may predispose the choroid to the same kind of vascular dysfunction.⁵ For people with recurrent CSCR, screening for sleep apnea and treating it if present is a reasonable part of the overall management plan.

Serous Detachment in Pregnancy

Pregnancy creates a hormonal and hemodynamic environment that can predispose to serous detachment through two different routes. The first is preeclampsia-driven choroidal ischemia, where high blood pressure damages choroidal vessels. The second is CSCR itself, which occurs at increased rates during pregnancy, likely due to elevated cortisol levels and shifts in fluid dynamics.⁶ The reassuring news is that both forms tend to resolve after delivery as hormone levels and blood pressure normalize. Still, sudden vision changes during pregnancy should be evaluated urgently because they can signal preeclampsia, which carries serious risks for both mother and baby far beyond the eyes.

When a pregnant woman develops bilateral serous detachments, the clinical team has to weigh the visual symptoms against the limited treatment options available during pregnancy. PDT and many systemic medications are typically avoided. In most cases, managing the underlying preeclampsia through blood pressure control and delivery when appropriate leads to spontaneous retinal reattachment.⁸

AI-Assisted Monitoring on the Horizon

One area of active development is the use of artificial intelligence to detect and quantify subretinal fluid on OCT scans. Fully automated deep-learning algorithms have already demonstrated high accuracy in identifying serous fluid, with strong correlations to expert manual measurements.¹⁷ The practical appeal is significant: if software can reliably flag small amounts of subretinal fluid that a busy clinician might miss, chronic conditions like CSCR could be caught and tracked more precisely during routine visits. Transfer learning approaches are extending this capability across different OCT machine brands, which matters because not every clinic uses the same equipment.¹⁸ None of this replaces a retinal specialist’s judgment, but it could make early detection more consistent, especially in settings where subspecialist access is limited.